ArticleFrontiers in immunology2026
Case Report: Anti-GT1a antibody-associated ocular flutter.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mounting evidence suggests that antiganglioside antibodies play a crucial role in the pathogenesis of Guillain-Barré syndrome (GBS) and its variants. Among them, anti-GT1a ganglioside immunoglobulin G (IgG) antibody (anti-GT1a IgG) is most strongly associated with cranial nerve involvement. We report a rare case of a 26-year-old woman who developed ocular flutter and mild ataxia following an upper respiratory tract infection. Neurological examination revealed rapid, conjugate horizontal saccadic oscillations without intersaccadic intervals, along with a mildly ataxic gait. Brain magnetic resonance imaging (MRI) and cerebrospinal fluid analysis were unremarkable. Serological testing revealed isolated positivity for anti-GT1a IgG, with negative results for other antibodies typically associated with paraneoplastic or autoimmune diseases, such as anti-GQ1b, anti-GM1, and anti-GM2 antibodies. The patient responded well to intravenous immunoglobulin (IVIG), with marked improvement in both ocular flutter and gait disturbance. Although this presentation does not fulfill the diagnostic criteria for classic GBS, it likely represents a restricted variant within the anti-GT1a antibody spectrum. This case highlights the importance of recognizing atypical manifestations of ganglioside-associated neuropathies and supports early immunotherapy as a key factor in favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.